Pharmaceutical Technology
MARCH 24, 2023
Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016.
Clarify Health
MARCH 1, 2023
1] In a separate, controlled study, 80 percent of primary care physicians receiving micro-incentives referred patients to higher-value specialists they had never used before — representing a significant reduction in the total cost of care. Healthcare (2016), [link] [2] Parikh, R. million on orthopedic MS-DRGs.[1]
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 2, 2022
Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and precision medicine targeting more niche patient populations. Using real-time data to track the trends at the physician level can be critical for successful enrolment in these scenarios. Getz, Kenneth.
PM360
MARCH 24, 2023
Starting with Vermont in 2016, more than half of the U.S. When the states realize that price discovery and competition already exist and that the real mark-ups take place at the pharmacy benefit manager (PBM) and retail pharmacy levels, manufacturers will have to comply and report.
PharmaKinnex
AUGUST 23, 2022
The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. Let’s dive into the current state of the pharma industry and learn more about what your team can do to stay ahead of the curve and the competition. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!
Evolve Your Success
MAY 23, 2023
With VR simulations, sales reps can now hone their skills in lifelike scenarios, giving them a competitive edge in the field. Osso was founded in 2016. My initial focus was I wanted to be a physician. I landed this competitive scholarship at the National Cancer Institute at school. How new is this space?
pharmaphorum
JUNE 29, 2022
Lockdowns are no longer; but the more hybrid model of physician and patient engagement is here to stay; the challenge for launching companies is how to optimise engagement impact and patient opportunity within them. Launches, therefore, were happening. But were they fulfilling their commercial potential?
Expert insights. Personalized for you.
59 
Let's personalize your content